The Ohio State University Corporate Engagement Office

Back to All Technologies

A Novel Microbial Therapeutic to Diminish the Risk of Arteriosclerosis and Subsequent Heart Disease

College
College of Arts & Sciences
Researchers
Krzycki, Joseph
Ferguson, Donald
Kountz, Duncan
Licensing Manager
Dahlman, Jason "Jay"
614/292-7945
dahlman.3@osu.edu

TS-037792 — Novel bacteria, specially formatted, as a microbial therapeutic for diminishing the risk of arteriosclerosis and subsequent heart disease.

Cardiovascular disease is the leading cause of mortality in the United States. Evidence is accumulating that certain human intestinal microbes contribute to atherosclerosis leading to cardiovascular disease, thereby increasing the risk of heart attack, stroke, and death. Gut microbes convert quate…

The Need

Cardiovascular disease is the leading cause of mortality in the United States. Evidence is accumulating that certain human intestinal microbes contribute to atherosclerosis leading to cardiovascular disease, thereby increasing the risk of heart attack, stroke, and death. Gut microbes convert quaternary amines (QAs), such as carnitine and choline, to trimethylamine (TMA). TMA enters the bloodstream and once converted by liver enzymes to trimethylamine –N-oxide (TMAO), can trigger macrophage mediated lipid deposition in the vascular system. Serum TMAO levels accordingly correlate with atherosclerosis and thus risk of stroke or heart attack. TMA production by QA lyases or reductases has long been considered the sole route of microbial degradation of QAs under the anaerobic condition prevalent in the gut, but recent evidence reveals a more complex microbial ecology.

The Technology

The Ohio State University researchers, led by Dr. Joseph Krzycki, have identified potential probiotics for the prevention of and defense against arteriosclerosis and heart disease. The inventors have identified certain strains of Eubacterium Limosum that are capable of demethylating QA precursors that would otherwise form TMA. By reducing the amount of TMA produced in the gut, risk of heart complications may decrease. Properly formulated microbial theraputics that utilizes these bacterial strains could be helpful for those at high risk of atherosclerosis and heart disease.

Commercial Applications

  • Prevention and Treatment of Artheriosclerosis

Benefits/Advantages

  • This technology offers a natural therapeutic method to decrease the risk of heart disease
  • The interplay between two defined microbial groups creates a homeostasis that keeps TMA levels in check, and which could be therapeutically manipulated